Merck said Q4 2024 sales were $15.6 billion, an increase of 7% from the prior-year quarter, and full-year sales were $64.2 billion, an increase of 7%. Full-year KEYTRUDA sales increased 18% to $29.5 billion.

1. 01

   Merck said Q4 2024 sales were $15.6 billion, an increase of 7% from the prior-year quarter, and full-year sales were $64.2 billion, an increase of 7%. Full-year KEYTRUDA sales increased 18% to $29.5 billion.

2. 02

   The company said Q4 2024 GAAP EPS was $1.48 and non-GAAP EPS was $1.72, while full-year GAAP EPS was $6.74 and non-GAAP EPS was $7.65. Full-year EPS included a net charge of $1.28 per share related to certain business development transactions.

3. 03

   Merck said full-year GARDASIL/GARDASIL 9 sales declined 3% to $8.6 billion. The company also said it decided to suspend shipments of GARDASIL/GARDASIL 9 to China beginning February 2025 through at least mid-year, and its 2025 sales outlook reflects this decision.

4. 04

   Merck anticipates full-year 2025 worldwide sales to be between $64.1 billion and $65.6 billion. The company expects non-GAAP EPS to be between $8.88 and $9.03, with the outlook reflecting a one-time charge of approximately $300 million related to an anticipated milestone payment to LaNova, or approximately $0.09 per share.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.